These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 29624882)

  • 21. Can influenza vaccination coverage among healthcare workers influence the risk of nosocomial influenza-like illness in hospitalized patients?
    Amodio E; Restivo V; Firenze A; Mammina C; Tramuto F; Vitale F
    J Hosp Infect; 2014 Mar; 86(3):182-7. PubMed ID: 24581755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Costs of in- and outpatient respiratory disease and the seasonal influenza vaccination program in Armenia - 2020-2021.
    Gobin S; Sahakyan G; Kusi Appiah M; Manukyan A; Palayan K; Ebama M; Vanyan A; McCarron M; Bresee J
    Vaccine; 2024 Oct; 42 Suppl 4(Suppl 4):126007. PubMed ID: 38839517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age.
    Allsup S; Gosney M; Haycox A; Regan M
    Health Technol Assess; 2003; 7(24):iii-x, 1-65. PubMed ID: 14499051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. School-Based Influenza Vaccination: Health and Economic Impact of Maine's 2009 Influenza Vaccination Program.
    Basurto-Dávila R; Meltzer MI; Mills DA; Beeler Asay GR; Cho BH; Graitcer SB; Dube NL; Thompson MG; Patel SA; Peasah SK; Ferdinands JM; Gargiullo P; Messonnier M; Shay DK
    Health Serv Res; 2017 Dec; 52 Suppl 2(Suppl 2):2307-2330. PubMed ID: 29130266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Assessment of efficacy and economic impact of an influenza vaccination campaign in the personnel of a health care setting].
    Cella MT; Corona G; Tuccillo E; Franco G
    Med Lav; 2005; 96(6):483-9. PubMed ID: 16983973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States.
    Clements KM; Chancellor J; Nichol K; DeLong K; Thompson D
    Value Health; 2011; 14(6):800-11. PubMed ID: 21914499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.
    Ryan J; Zoellner Y; Gradl B; Palache B; Medema J
    Vaccine; 2006 Nov; 24(47-48):6812-22. PubMed ID: 17034909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia.
    Newall AT; Scuffham PA; Kelly H; Harsley S; Macintyre CR
    Vaccine; 2008 Apr; 26(17):2142-53. PubMed ID: 18343537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.
    Crépey P; Boiron L; Araujo RR; Lopez JG; Petitjean A; de Albuquerque Luna EJ
    BMC Public Health; 2020 Sep; 20(1):1374. PubMed ID: 32907562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influenza vaccination in health-care workers: an evaluation of an on-site vaccination strategy to increase vaccination uptake in HCWs of a South Italy Hospital.
    Vimercati L; Bianchi FP; Mansi F; Ranieri B; Stefanizzi P; De Nitto S; Tafuri S
    Hum Vaccin Immunother; 2019; 15(12):2927-2932. PubMed ID: 31157586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Cost of Interventions to Increase Influenza Vaccination: A Systematic Review.
    Anderson LJ; Shekelle P; Keeler E; Uscher-Pines L; Shanman R; Morton S; Aliyev G; Nuckols TK
    Am J Prev Med; 2018 Feb; 54(2):299-315. PubMed ID: 29362167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outbreak of influenza A (2009) H1N1 among Thai healthcare workers: is it time to integrate a vaccination program?
    Apisarnthanarak A; Mundy LM
    Infect Control Hosp Epidemiol; 2010 Aug; 31(8):854-6. PubMed ID: 20569113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness study on influenza prevention in Hong Kong.
    Fitzner KA; Shortridge KF; McGhee SM; Hedley AJ
    Health Policy; 2001 Jun; 56(3):215-34. PubMed ID: 11399347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Public health and economic benefits of new pediatric influenza vaccination programs in Argentina.
    Giglio N; Gentile A; Lees L; Micone P; Armoni J; Reygrobellet C; Crépey P
    Hum Vaccin Immunother; 2012 Mar; 8(3):312-22. PubMed ID: 22330959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protecting patients, protecting healthcare workers: a review of the role of influenza vaccination.
    Music T
    Int Nurs Rev; 2012 Jun; 59(2):161-7. PubMed ID: 22591085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
    Kim YK; Song JY; Jang H; Kim TH; Koo H; Varghese L; Han E
    Pharmacoeconomics; 2018 Dec; 36(12):1475-1490. PubMed ID: 30251078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland.
    Nagy L; Heikkinen T; Sackeyfio A; Pitman R
    Pharmacoeconomics; 2016 Sep; 34(9):939-51. PubMed ID: 27423657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children.
    Luce BR; Zangwill KM; Palmer CS; Mendelman PM; Yan L; Wolff MC; Cho I; Marcy SM; Iacuzio D; Belshe RB
    Pediatrics; 2001 Aug; 108(2):E24. PubMed ID: 11483834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial.
    Bridges CB; Thompson WW; Meltzer MI; Reeve GR; Talamonti WJ; Cox NJ; Lilac HA; Hall H; Klimov A; Fukuda K
    JAMA; 2000 Oct; 284(13):1655-63. PubMed ID: 11015795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain.
    Aballéa S; De Juanes JR; Barbieri M; Martin M; Chancellor J; Oyagüez I; Verwee B; Largeron N
    Vaccine; 2007 Sep; 25(39-40):6900-10. PubMed ID: 17764790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.